Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc > CPH's Hospital Products: Deal with Verity -> Revenue Growth

<< Previous

Bullboard Posts

Next >>

Comment by stockfyon Mar 04, 2021 2:47am

81 Views

Post# 32712539

RE:CPH's Hospital Products: Deal with Verity -> Revenue Growth

Facts here about the recent deal with Verity.

stockfy wrote:

Good news. CPH just announced a deal for its hospital products that will contribute to revenue growth in the next months:

https://cipher.investorroom.com/2021-02-10-Cipher-Pharmaceuticals-Enters-into-Co-Promotion-Agreement-with-Verity-Pharmaceuticals-Inc

"Under the terms of the Agreement, Verity will be responsible for the co-promotion of all hospital products inclusive of all costs and expenses associated with those products. Verity will be compensated by receiving a tiered percentage of the net margin of the products."

Meanwhile, debt-free and profitable CPH is working on additional growth opportunities, according to the latest CC:

"The COVID-19 pandemic continued to impact the economy during the third quarter of 2020. Cipher is navigating through this environment while executing on business improvements and cost reductions. Cipher demonstrated strong profitability during the third quarter and sequential growth in revenue, despite market conditions that have not fully normalized. Our focus continues to be on driving profitability, strengthening the balance sheet and looking for the right opportunities for growth. "